New Products
Drug Name Strength Qty Price
Aciphex (Pariet in Canada) 20 mg 84 $179.25
Alendronate (Fosamax) (generic) 10 mg 30 $41.29
Altace (Ramipril) 1.25 mg 90 $62.60
Bextra (valdecoxib) 10 mg 100 $147.15
Bextra (valdecoxib) 20 mg 100 $147.15
Brimonidine Eyedrops (Alphagan) (generic) 0.2% 10 mL $32.59
Budesonide AQ 100 mcg 1 vial $19.99
Aliment Pharmacol Ther. 2003 Jun;17 Suppl 2:23-30.:
Medical treatment of moderate to severe Crohn's disease.
Scribano M, Prantera C.
Division of Gastroenterology, Azienda Ospedaliera S.Camillo-Forlanini, Rome, Italy.
The treatment for patients with Crohn's disease of moderate to severe activity includes traditional drugs, such as corticosteroids, the primary therapy for these forms of disease, able to induce the remission of symptoms in a high percentage of patients. Because of the side-effects produced by systemic steroids, a new glucocorticoid derivative, budesonide, which acts locally in the mucosa, has recently been introduced with positive results. On the assumption that intestinal bacteria play a role in the causing Crohn's disease symptoms, antibiotics are often used in the treatment of active phases, as an alternative to or in association with steroids. The most widely employed antibiotics are metronidazole and ciprofloxacin. Immunosuppressors, such as azathioprine and 6-mercaptopurine, are useful for the treatment of chronic active disease and for maintaining remission, but they have only a marginal role in the therapy of an acute flare-up of Crohn's disease. Methotrexate acts more rapidly and its use in patients with active disease resistant to standard therapy is of interest. The discovery of biological agents represents a new era in the management of patients. To date, infliximab is the more extensively studied biological therapy in the treatment of Crohn's disease and clinical studies have demonstrated its efficacy in inducing remission of refractory disease
Clarinex (Aerius in Canada) 5 mg 30 $24.99
Claritin D 12h (with decongestant) (non-rx) 30 $17.99
Claritin D 24h (called Liberator in Canada) (non-rx) 30 $39.99
Detrol LA (Tolterodine) 4 mg 90 $163.23
Detrol LA (Tolterodine) 2 mg 90 $157.94
Ezetrol (ezetimibe) (Zetia in USA) 10 mg 100 $189.99
Fosamax (Alendronate) 70 mg 4 $45.57
Lamotrigine (generic Lamictal) 150 mg 100 $126.18
Lamotrigine (generic Lamictal) 100 mg 100 $107.70
Lamotrigine (generic Lamictal) 25 mg 100 $50.96
Micardis HCT 80/12.5 mg 28 $30.85
Reminyl (galantamine) 4 mg 60 $106.05
Reminyl (galantamine) 8 mg 60 $106.05
Reminyl (galantamine) 12 mg 60 $106.05
Simvastatin (generic Zocor) 5 mg 100 $84.16
Simvastatin (generic Zocor) 10 mg 100 $121.85
Simvastatin (generic Zocor) 20 mg 100 $157.33
Simvastatin (generic Zocor) 40 mg 100 $168.49
Simvastatin (generic Zocor) 80 mg 100 $171.16
Spiriva (Tiotropium bromide) 18 mcg 30 $74.89
Starlix (Nateglinide) 60 mg 84 $57.94
Diabetologia. 2003 Mar;46 Suppl 1:M37-43. Epub 2002 Nov 08. :
The mechanisms underlying the unique pharmacodynamics of nateglinide.
Hu S, Boettcher BR, Dunning BE.
Novartis Institute for Biomedical Research, 556 Morris Avenue, LSB 2287 Summit, New Jersey 07901, USA, Shiling.
Hu@pharma.novartis.com
Nateglinide, a D-phenylalanine derivative, belongs to a new group of insulinotropic agents with rapid onset and short duration of action. These agents have been developed to reduce the risk of hypoglycaemia associated with pharmacological control and to decrease the likelihood of pancreatic beta-cell exhaustion. Nateglinide mediates the release of insulin from beta-cells by binding to the sulphonylurea receptors, which leads to the closure of ATP-sensitive K(+) channels. Increasing evidence from receptor binding, mechanistic and in vitro and in vivo insulin studies indicate unique pharmacodynamic and pharmacokinetic properties with nateglinide that are distinct from those of sulphonylureas. The time required by nateglinide to close beta-cell K(ATP) channels is comparable to that of glyburide but threefold and fivefold faster than repaglinide and glimepiride, respectively. Furthermore, its effects are rapidly reversed with an off-rate at the K(ATP) channel twice as fast as that of glyburide and glimepiride and five times faster than repaglinide. This results in a rapid and short insulin response characteristic of the physiological pattern of post-mealtime insulin release. Internalisation into beta-cells is not required for the action of nateglinide. Given that the kinetic profile of the agent is associated with selective enhancement of early-phase insulin secretion, nateglinide is expected to minimise post-meal hyperglycaemia with minimal propensity for hypoglycaemia.
Diabetes Care. 2003 Jun;26(6):1685-90. :
Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.
Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE.
Tulane University Medical Center, New Orleans, Louisiana. Grunberger Diabetes Institute, Bloomfield Hills, Michigan. Novartis Pharmaceuticals, East Hanover, New Jersey.
OBJECTIVE-To determine the effects of nateglinide added to rosiglitazone monotherapy on glycemic control and on postprandial glucose and insulin levels in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS-This 24-week, multicenter, double-blind, randomized study compared the efficacy of nateglinide (120 mg a.c.) and placebo added to rosiglitazone monotherapy (8 mg q.d.) in 402 patients with type 2 diabetes with HbA(1c) between 7 and 11% (inclusive). Efficacy parameters tested included HbA(1c) and plasma glucose and insulin levels in the fasting state and after a standardized meal challenge. Safety data were also collected. RESULTS:-In placebo-treated patients, HbA(1c) did not change (Delta = 0.0 +/- 0.1%). In patients randomized to nateglinide, HbA(1c) decreased from 8.3 to 7.5% (Delta = -0.8 +/- 0.1%, P < 0.0001 vs. placebo). Target HbA(1c) (<7.0%) was achieved by 38% of patients treated with combination therapy and by 9% of patients remaining on rosiglitazone monotherapy. In nateglinide-treated patients, fasting plasma glucose levels decreased by 0.7 mmol/l, 2-h postprandial glucose levels decreased by 2.7 mmol/l, and 30-min insulin levels increased by 165 pmol/l compared with no changes from baseline of these parameters with placebo added to rosiglitazone (P < 0.001). CONCLUSIONS:-By selectively augmenting early insulin release and decreasing prandial glucose excursions, nateglinide produced a clinically meaningful improvement in overall glycemic exposure in patients with type 2 diabetes inadequately controlled with rosiglitazone. Therefore, nateglinide substantially improves the likelihood of achieving a therapeutic target of HbA(1c) <7.0%.
Starlix (Nateglinide) 80 mg 84 $58.15
Starlix (Nateglinide) 120 mg 84 $59.23
Travatan Eyedrops 0.004% 2.5 mL $34.31
Ultrase MT 12 mg 100 $45.12
